Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AURA

AURA - Aura Biosciences, Inc. Stock Price, Fair Value and News

9.15USD+0.41 (+4.69%)Market Closed
Watchlist

Market Summary

USD9.15+0.41
Market Closed
4.69%

AURA Alerts

  • CITADEL ADVISORS LLC reported owning 7.2% of AURA [2024-02-14]
  • 1 major insider sales recently.

AURA Stock Price

View Fullscreen

AURA RSI Chart

AURA Valuation

Market Cap

350.1M

Price/Earnings (Trailing)

-4.94

Price/Free Cashflow

-5.37

AURA Price/Earnings (Trailing)

AURA Profitability

Return on Equity

-46.69%

Return on Assets

-39.4%

Free Cashflow Yield

-18.63%

AURA Fundamentals

AURA Earnings

Earnings (TTM)

-70.8M

Earnings Growth (Yr)

-16.42%

Earnings Growth (Qtr)

-1.16%

Breaking Down AURA Revenue

Last 7 days

2.4%

Last 30 days

5.6%

Last 90 days

9.1%

Trailing 12 Months

-17.7%

How does AURA drawdown profile look like?

AURA Financial Health

Current Ratio

14.13

AURA Investor Care

Shares Dilution (1Y)

30.43%

Diluted EPS (TTM)

-1.94

Tracking the Latest Insider Buys and Sells of Aura Biosciences, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
hopkins janet jill
acquired
-
-
28,515
chief medical officer
Feb 01, 2024
feder julie b
acquired
-
-
71,285
chief financial officer
Feb 01, 2024
de los pinos elisabet
acquired
-
-
162,935
see remarks
Jan 23, 2024
de los pinos elisabet
sold
-121,141
7.6415
-15,853
see remarks
Jan 23, 2024
feder julie b
sold
-50,521
7.6443
-6,609
chief financial officer
Nov 09, 2023
matrix capital management company, lp
bought
14,040,000
9.00
1,560,000
-
Nov 08, 2023
johnson david michael
bought
70,087
7.3
9,601
-
Nov 08, 2023
johnson david michael
bought
73,000
7.3
10,000
-
Nov 07, 2023
johnson david michael
bought
544,920
7.17
76,000
-

1–10 of 50

Which funds bought or sold AURA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
added
91.83
24,278,400
51,411,800
0.84%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
0.41
-50,000
5,845,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-161,000
-
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
-255
20,573
-%
Feb 15, 2024
BARCLAYS PLC
added
683
295,000
338,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
255,052
255,052
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
255
16,750,600
23,423,400
0.70%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
reduced
-13.56
-53,800
314,176
-%
Feb 14, 2024
Ensign Peak Advisors, Inc
new
-
3,164,990
3,164,990
0.01%
Feb 14, 2024
Nuveen Asset Management, LLC
added
16.86
83,175
622,407
-%

1–10 of 48

Are Funds Buying or Selling AURA?

Are funds buying AURA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AURA
No. of Funds

Unveiling Aura Biosciences, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
citadel advisors llc
7.2%
6
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
8.61%
4,225,000
SC 13G/A
Dec 11, 2023
eventide asset management, llc
11.82%
5,802,682
SC 13G/A
Nov 09, 2023
matrix capital management company, lp
14.10%
6,922,870
SC 13D/A
Feb 14, 2023
citadel advisors llc
7.4%
6
SC 13G/A
Feb 14, 2023
eventide asset management, llc
6.3%
2,251,368
SC 13G
Feb 10, 2023
arix bioscience plc
4.1%
1,508,483
SC 13G/A
Feb 09, 2023
adage capital partners gp, l.l.c.
5.76%
2,132,739
SC 13G/A
Jan 20, 2023
chiesi ventures, inc.
3.3%
1,218,803
SC 13G/A
Dec 15, 2022
adage capital partners gp, l.l.c.
5.65%
2,090,665
SC 13G

Recent SEC filings of Aura Biosciences, Inc.

View All Filings
Date Filed Form Type Document
Feb 23, 2024
144
Notice of Insider Sale Intent
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
4
Insider Trading
Jan 24, 2024
144
Notice of Insider Sale Intent
Jan 24, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Aura Biosciences, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.2B
396.6M
-2.06% 34.31%
-15.49
20.64
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
3.9B
631.9M
-12.60% 32.37%
-26.2
6.17
23.54% 31.53%
SMALL-CAP
1.6B
348.4M
-3.38% -9.50%
25.02
4.46
81.69% -7.29%
521.5M
1.0B
-9.17% -57.89%
-0.95
0.5
-43.15% 58.48%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aura Biosciences, Inc. News

Latest updates
BNN Breaking26 Feb 202412:05 pm
Marketscreener.com26 Feb 202412:01 pm
Simply Wall St10 Feb 202408:00 am
Stock Traders Daily.com07 Feb 202406:56 pm
GuruFocus.com06 Feb 202404:00 am

Aura Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-6.7%18019320622414313514616091.0068.0045.0022.00
  Current Assets-7.4%15416617919711612814015483.00--18.00
    Cash Equivalents16.5%56.0048.0038.0012261.0054.0010814982.0092.0010017.00
  Net PPE-4.0%5.005.005.005.005.006.006.005.004.00--4.00
Liabilities6.6%28.0026.0026.0028.0028.006.005.008.006.005.004.003.00
  Current Liabilities22.5%11.009.008.0010.0010.006.005.007.006.00--3.00
Shareholder's Equity-8.8%1521661801961151291411529.009.009.008.00
  Retained Earnings-7.5%-265-246-228-210-194-178-164-152-140---116
  Additional Paid-In Capital0.9%4174134094073103083063049.00--8.00
Shares Outstanding0.3%38.0038.0038.0038.0029.0029.0029.0029.00--0.000.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Cashflow From Operations-5.2%-15,403-14,645-16,412-18,013-10,760-10,628-15,200-12,086-8,690-6,497-5,137--
  Share Based Compensation20.4%2,3251,9311,9131,8141,7171,2871,5941,297554271185--
Cashflow From Investing1.0%21,62921,407-66,879-16,87617,946-43,441-25,498-819-573-662-71.00--
Cashflow From Financing-34.4%1,6262,47820195,19910430917.0080,142-1,116-25687,489--

AURA Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating Expenses:    
Research and development$ 15,428$ 11,293$ 44,952$ 29,079
General and administrative5,0604,76215,25613,603
Total operating expenses20,48816,05560,20842,682
Total operating loss(20,488)(16,055)(60,208)(42,682)
Other income (expense):    
Interest income, including amortization and accretion income1,9814835,981802
Other income (expense)(5)(329)(50)(324)
Total other income1,9761545,931478
Net loss$ (18,512)$ (15,901)$ (54,277)$ (42,204)
Net loss per common share - basic$ (0.48)$ (0.54)$ (1.43)$ (1.44)
Net loss per common share - diluted$ (0.48)$ (0.54)$ (1.43)$ (1.44)
Weighted average common stock outstanding - basic38,185,19729,273,57737,943,13929,246,449
Weighted average common stock outstanding - diluted38,185,19729,273,57737,943,13929,246,449
Comprehensive loss:    
Net loss$ (18,512)$ (15,901)$ (54,277)$ (42,204)
Other comprehensive items:    
Unrealized gain (loss) on marketable securities89(19)(62)(147)
Total other comprehensive income (loss)89(19)(62)(147)
Total comprehensive loss$ (18,423)$ (15,920)$ (54,339)$ (42,351)

AURA Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 55,584$ 121,582
Marketable securities93,47267,229
Restricted cash and deposits2020
Prepaid expenses and other current assets4,8127,871
Total current assets153,888196,702
Restricted cash and deposits, net of current portion768768
Right of use assets - operating lease19,56920,671
Other long-term assets685423
Property and equipment, net4,8565,371
Total Assets179,766223,935
Current liabilities:  
Accounts payable1,4902,921
Short-term operating lease liability3,0352,963
Accrued expenses and other current liabilities6,3694,573
Total current liabilities10,89410,457
Long-term operating lease liability17,15417,895
Total Liabilities28,04828,352
Commitments and Contingencies (Note 12)
Stockholders Equity:  
Common stock, $0.00001 par value, 150,000,000 authorized at September 30, 2023 and December 31, 2022, and 38,216,717 and 37,771,918 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Additional paid-in capital417,029406,555
Accumulated deficit(265,177)(210,900)
Accumulated other comprehensive loss(134)(72)
Total Stockholders' Equity151,718195,583
Total Liabilities and Stockholders Equity$ 179,766$ 223,935
AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.aurabiosciences.com
 EMPLOYEES70

Aura Biosciences, Inc. Frequently Asked Questions


What is the ticker symbol for Aura Biosciences, Inc.? What does AURA stand for in stocks?

AURA is the stock ticker symbol of Aura Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aura Biosciences, Inc. (AURA)?

As of Wed Feb 28 2024, market cap of Aura Biosciences, Inc. is 350.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AURA stock?

You can check AURA's fair value in chart for subscribers.

What is the fair value of AURA stock?

You can check AURA's fair value in chart for subscribers. The fair value of Aura Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aura Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AURA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aura Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether AURA is over valued or under valued. Whether Aura Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Aura Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AURA.